Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder.
| Publicado en: | Psychopharmacology Vol. 221; no. 4; pp. 601 - 611 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jun2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104335971&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104335971 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00333158 EJD jtl: Psychopharmacology issn: 00333158 maglogo: N pubinfo: dt: Jun2012 vid: 221 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104335971 2011957294 10.1007/s00213-011-2604-x 104335971 ppf: 601 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder. aug: au: Riesenberg, Robert Rosenthal, Joshua Moldauer, Leslie Peterson, Christine affil: Atlanta Center for Medical Research, Atlanta USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|